

REMARKS

Claim Amendments

Claims 44–71 are pending in the Application. Claims 58–71 are canceled by Applicant without prejudice. Claim 44 has been amended. Support for the claim amendments is found throughout the specification and in the originally filed claims. No new matter has been added.

Applicant has amended claim 44 simply and strictly so as to rearrange gene identifications listed therein in alphabetical order.

Specifically, the claim 44 recitation “zinc finger protein (Hs.47371); zinc finger protein (Hs.78765); zinc finger protein 10 (KOX 1) (ZNF10); zinc finger protein 136 (clone pHZ-20) (ZNF136); zinc finger protein 140 (clone pHZ-39) (ZNF140); zinc finger protein 143 (clone pHZ-1) (ZNF143); zinc finger protein 148 (pHZ-52) (ZNF148); zinc finger protein 173 (ZNF173); zinc finger protein 198 (ZNF198); zinc finger protein 200 (ZNF200); zinc finger protein 207 (ZNF207); zinc finger protein 216 (ZNF216); zinc finger protein 217 (ZNF217); zinc finger protein 230 (ZNF230); Zinc finger protein 239 (ANF239); zinc finger protein 261 (ZNF261); zinc finger protein 262 (ANF262); zinc finger protein 263 (ZNF263); zinc finger protein 264 (ZNF264); zinc finger protein 42 (myeloid-specific retinoic cid- responsive) (ZNF42); zinc finger protein 45 (a Kruppel-associated box (KRAB) domain polypeptide) (ZNF45); zinc finger protein 76 (expressed in testis) (ZNF76); zinc finger protein 84 (HPF2) (ZNF84); zinc finger protein 85 (ZNF85)); zinc finger protein 9 (ZNF9); zinc finger protein C2H2-25 (ZNF25); zinc finger protein clone L3-4; zinc finger protein homologous to Zfp-36 in mouse (ZFP36); zinc finger protein HZF4; zinc finger protein RIZ; zinc finger protein, subfamily 1A, 1 (Ikaros) (LYF1);” has been relocated so as to immediately follow the recitation “zinc-finger helicase (hZFH); ”.

Further specifically, the claim 44 recitation “zinc finger transcriptional regulator (GOS24);” has been relocated so as to immediately precede the recitation “Zn-15 related zinc finger protein (rlf)”.

Conclusion

Applicant submits that all claims are allowable as written and respectfully requests early favorable action by the Examiner. If the Examiner believes that a telephone conversation with Applicant's attorney/agent would expedite prosecution of this application, the Examiner is cordially invited to call the undersigned attorney/agent of record.

Should any fees be required to ensure consideration of this supplemental response, the Commissioner is authorized to charge Deposit Account 04-1105, Reference No. 2053B(204231).

Respectfully submitted,

Date: November 24, 2009

/Amy DeCloux/

Name: Kathleen M. Williams

Registration No.: 34,380

Name: Amy DeCloux

Registration No.: 54,849

Customer No.: 21874

Edwards Angell Palmer & Dodge LLP

P.O. Box 55874

Boston, MA 02205

Tel: 617-239-0100